Last reviewed · How we verify
Prevention of CMV Disease After Cardiac Transplantation
Approved treatments
- Valcyte · Cheplapharm
Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor. - Cytovene · Roche Palo
GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of CMV Disease After Cardiac Transplantation patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of CMV Disease After Cardiac Transplantation treatment landscape brief
- Prevention of CMV Disease After Cardiac Transplantation treatment updates RSS
Frequently asked questions about Prevention of CMV Disease After Cardiac Transplantation
What drugs treat Prevention of CMV Disease After Cardiac Transplantation?
Tracked treatments include Valcyte, Cytovene.
What is the treatment for Prevention of CMV Disease After Cardiac Transplantation?
Standard treatment for Prevention of CMV Disease After Cardiac Transplantation includes Valcyte, Cytovene. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of CMV Disease After Cardiac Transplantation patent cliff · Prevention of CMV Disease After Cardiac Transplantation CI report
- Treatment: Valcyte · Cheplapharm
- Treatment: Cytovene · Roche Palo
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing